Increased urinary excretion of carnitine in patients treated with cisplatin

European Journal of Clinical Pharmacology

Volumn 54, Issue 7, 1998, Pages 503-508

  Heuberger, W ^a   Berardi, S ^a   Jacky, E ^a   Pey, P ^b   Krahenbuhl S ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cisplatin; Hypocarnitinaemia

Indexed keywords

ACYLCARNITINE; CARNITINE; CISPLATIN;

ADULT; ARTICLE; CACHEXIA; CARNITINE DEFICIENCY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; HUMAN; KIDNEY PROXIMAL TUBULE; MALE; PRIORITY JOURNAL; RADIOENZYMATIC ASSAY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; CARNITINE; CISPLATIN; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PHOSPHATES;

EID: 0031766909     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050504     Document Type: Article

References (24)

1. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13: 228-244
2. Groth S, Nielsen H, Sorensen JB, Christensen AB, Pedersen AG, Rorth M (1986) Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 17: 191-196
3. Falkenberg FW, Mondorf U, Pierard D, et al (1987) Identification of fragments of proximal and distal tubular cells in the urine of patients under cytostatic treatment by immunoelectron microscopy with monoclonal antibodies. Am J Kidney Dis IX: 129-137
4. Lam M, Adelstein DJ (1986) Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis VIII: 164-169
5. Schilsky RL, Barlock A, Ozols RF (1982) Persistent hypomagnesaemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 66: 1767-1769
6. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Leyssac PP (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44: 164-172
7. Jones BR, Bhalla RB, Mladek J et al (1980) Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther 27: 557-562
8. Sugiyama S, Hayakawa M, Kato T, Hanaki Y, Shimizu K, Ozawa T (1989) Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: disturbances in glutathione peroxidase activity. Biochem Biophys Res Comm 159: 1121-1127
9. Zhang JG, Lindup WE (1993) Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 45: 2215-2222
10. Bremer J (1983) Carnitine metabolism and functions. Physiol Rev 63: 1421-1466
11. McGarry JD, Brown NF (1997) The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244: 1-14
12. Hoppel CL, Davis AT (1986) Inter-tissue relationships in the synthesis and distribution of carnitine. Biochem Soc Trans 14: 673-674
13. Stieger B, O'Neill B, Krähenbühl S (1995) Characterization of L-carnitine transport by rat kidney brush-border-membrane vesicles. Biochem J 309: 643-7
14. Rebouche CJ, Mack DL (1984) Sodium gradient-stimulated transport of L-carnitine into renal brush border membrane vesicles: kinetics, specificity, and regulation by dietary carnitine. Arch Biochem Biophys 235: 393-402
15. Steinmann B, Bachmann C, Colombo JP, Gitzelmann R (1987) The renal handling of carnitine in patients with selective tubulopathy and with Fanconi syndrome. Pediatr Res 21: 201-204
16. Bernardini I, Rizzo WB, Dalakas M, Bernar J, Gahl WA, (1985) Plasma and muscle free carnitine deficiency due to renal Fanconi syndrome. J Clin Invest 75: 1124-1130
17. Cederblad G, Lindstedt S (1972) A method for the determination of carnitine in the picomolar range. Clin Chim Acta 37: 235-243
18. Brass EP, Hoppel CL (1978) Carnitine metabolism in the fasting rat. J Biol Chem 253: 2688-2693
19. Krähenbühl S, Reichen J (1996) Carnitine metabolism in patients with chronic liver disease. Hepatology 25: 148-153
20. Friolet R, Hoppeler H, Krähenbühl S (1994) Relationship between the coenzyme A and the carnitine pools in human skeletal muscle at rest and after exhaustive exercise under normoxic and acutely hypoxic conditions. J Clin Invest 94: 1490-1495
21. Zhang JG, Zhong LF, Zhang M, Xia YX (1992) Protection effects of procaine on oxidative stress and toxicities of renal cortical slices from rats caused by cisplatin in vitro. Arch Toxicol 66: 354-358
22. Daley-Yates PT, McBrien DCH (1982) The inhibition of renal ATPase by cisplatin and some bio-transformation products. Chem Biol Interact 40: 325-334
23. Uozumi J, Litterst CI (1985) The effect of cisplatin on renal ATPase activity in vivo and in vitro. Cancer Chemother Pharmacol 15: 93-96
24. Dodson WL, Sachan DS, Krauss S, Hanna W (1989) Alterations of serum and urinary carnitine profile in cancer patients: hypothesis of possible significance. J Am Coll Nut 8: 133-142